RayzeBio

Bristol Myers Squibb Makes Another M&A Move, Striking $4B Deal for RayzeBio

By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.

By Frank Vinluan

BioPharma, Pharma

RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials

RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.

By Frank Vinluan